key: cord-1007268-mbrx8jv5
authors: Curreli, Francesca; Victor, Sofia M B; Ahmed, Shahad; Drelich, Aleksandra; Tong, Xiaohe; Tseng, Chien-Te K; Hillyer, Christopher D.; Debnath, Asim K
title: Stapled peptides based on Human Angiotensin-Converting Enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro
date: 2020-11-11
journal: bioRxiv
DOI: 10.1101/2020.08.25.266437
sha: 12144e3fba6fe13aee683f2cfd6781134b2a920c
doc_id: 1007268
cord_uid: mbrx8jv5

SARS-CoV-2 uses human angiotensin-converting enzyme 2 (ACE2) as the primary receptor to enter host cells and initiate the infection. The critical binding region of ACE2 is a ∼30 aa long helix. Here we report the design of four stapled peptides based on the ACE2 helix, which is expected to bind to SARS-CoV-2 and prevent the binding of the virus to the ACE2 receptor and disrupt the infection. All stapled peptides showed high helical contents (50-94% helicity). On the contrary, the linear control peptide NYBSP-C showed no helicity (19%). We have evaluated the peptides in a pseudovirus based single-cycle assay in HT1080/ACE2 and human lung cells A549/ACE2, overexpressing ACE2. Three of the four stapled peptides showed potent antiviral activity in HT1080/ACE2 (IC50: 1.9 – 4.1 µM) and A549/ACE2 cells (IC50: 2.2 – 2.8 µM). The linear peptides NYBSP-C and the double-stapled peptide StRIP16, used as controls, showed no antiviral activity. Most significantly, none of the stapled peptides show any cytotoxicity at the highest dose tested. We also evaluated the antiviral activity of the peptides by infecting Vero E6 cells with the replication-competent authentic SARS-CoV-2 (US_WA-1/2020). NYBSP-1 was the most efficient preventing the complete formation of cytopathic effects (CPEs) at an IC100 17.2 µM. NYBSP-2 and NYBSP-4 also prevented the formation of the virus-induced CPE with an IC100 of about 33 µM. We determined the proteolytic stability of one of the most active stapled peptides, NYBSP-4, in human plasma, which showed a half-life (T1/2) of >289 min.

A novel and highly pathogenic coronavirus named SARS-CoV-2 was first identified in Wuhan, China, in 2019. It causes Coronavirus disease 2019 (COVID- 19) , and the resultant rapid global spread is a substantial threat to public health and the world economy. On March 11, 2020 providing some benefit to COVID-19 patients. Several vaccines and other repurposed therapeutics are also in clinical trials. SARS-CoV-2, like its predecessor SARS-CoV, uses its receptor-binding domain (RBD) in the S1 spike protein to initiate entry by binding to human host receptor angiotensin-converting enzyme 2 (ACE2). Recently, soluble human ACE2 (hACE2) has been proposed as a competitive interceptor of SARS-CoV 1 , and a recombinant hACE2 (rhACE2)

is now undergoing a clinical trial 2 . However, a recent report indicated that in both humans and mice, rACE2 had a fast clearance rate, and the half-life was only hours by pharmacokinetic studies 3, 4 . Recently, it was shown that when ACE2 was fused with an Fc fragment ACE2-Ig it showed high-affinity binding to the RBD of both SARS-CoV and SARS-CoV-2. ACE2-Ig also exhibited potent neutralization of SARS-CoV-2 with improved pharmacological properties in mice 5 . Despite the potential of recombinant ACE2, in a dire global pandemic situation, proteinbased therapy may not be suitable for use, especially in more developing nations, primarily due to the high cost and stability of protein-based therapy. Therefore, we sought to design therapeutics that are more stable and less expensive to make for wider distribution. Recently, Zhang et al. reported a 23-mer peptide (SBP1) from the ACE2 α1 helix sequence, which showed a potent binding affinity (K D =47 nM) to the SARS-CoV-2 RBD. However, there was no antiviral activity data reported 6 . We envision that this type of short linear peptides will not be stable against proteolysis and, most significantly, may not have the right secondary structure required for efficient binding with the SARS-CoV-2 RBD.

Recent Cryo-EM and X-ray structures of the SARS-CoV-2 RBD with full-length ACE2 revealed structural details of the binding interactions of these two proteins [7] [8] [9] [10] . A close inspection revealed that the interaction surface is long and flat, which may not be conducive to design small-molecule drugs to prevent protein-protein interactions. Interestingly, however, the structure also revealed that one of the long α-helix (herein termed Helix-1) interacts with the RBD consisting of multiple binding "hot spots." Based on this structural insight, we designed stapled peptides based on the binding site of SARS-CoV-2 RBD on the ACE2 receptor (Helix-1), which are expected to act as a decoy receptor preventing the binding of SARS-CoV-2 to the host receptor ACE2 (Figure 1) hence virus entry to host cells. Targeting the entry pathway of SARS-CoV-2 is ideal for both prevention and treatment as it blocks the first step of the viral life cycle.

Protein-protein interactions (PPI) between host and virus are valuable targets to inhibit viral replication. However, the large and flat interacting surfaces of PPI often preclude the use of small molecules as drugs to disrupt these PPI. Larger biologics, such as peptidomimetics (e.g., hydrocarbon-stapled-peptide mimetics), are, on the other hand, promising inhibitors of PPI that were previously intractable [11] [12] [13] [14] . Stapled peptides are typically derived from the α-helix from the binding interface, and they are locked into bioactive conformations through the use of chemical linkers. Stapling enhances α-helicity of unstructured short peptides in solution, improves resistance against proteolytic digestion, as well as potency, and often improves cell penetration [15] [16] [17] [18] [19] [20] [21] Here, we took advantage of Helix-1 of ACE2 to design peptide-based therapeutics for COVID-19. However, Helix-1 is expected to lose its helical conformation in solution; therefore, it will also lose the orientation of most, if not all, of the binding site residues to make any proper interaction.

To counter this, we adopted the very well-studied concept of hydrocarbon stapling techniques mentioned above to reinforce the bioactive helical conformation of Helix-1 (Figure 2) . We hypothesize that stapled peptides will be α-helical and will be proteolytically stable. They are expected to bind to the SARS-CoV-2 RBD and inhibit virus entry to cells.

In this report, we present the design of four such stapled peptides based on Helix-1 of ACE2.

Three of these peptides showed potent SARS-CoV-2 inhibitory activity in an in vitro pseudovirus and in an authentic virus infectivity assay. These stapled peptides have the potential as a therapeutic for COVID-19 by functioning as a decoy of ACE2 binding site for SARS-CoV-2 and preventing the virus from binding to the ACE2 receptor; thereby preventing virus entry and infection.

Recently solved structures by Cryo-EM and X-rays provided intricate details on how SARS-CoV-2 RBD binds to the host receptor ACE2. The major binding sites are located on Helix-1 of ACE2 (Figure 1) . A recent report indicated that a computationally designed short peptide from Helix-1 of ACE2 showed a nanomolar binding affinity to SARS-CoV-2 RBD 6 . However, the usefulness of such a linear peptide in isolation as a drug is yet to be proven. In general, when a helix is taken out as a peptide from a protein, it loses its secondary structure. These peptides are also prone to proteolytic degradation. On the contrary, if such small peptides are constrained by hydrocarbon stapling, an enhancement of helical content can be achieved together with resistance to proteolysis and improved binding affinity and biological activity 11-21, 23, 24 . Therefore, we envisioned that the stapling of Helix-1 will render it α-helical, resistant to proteolysis, and, therefore, a highly potent inhibitor of SARS-CoV-2.

i/i+4 and i/i+7 hydrocarbon stapling. We used the well-established stapling techniques to synthesize hydrocarbon-stapled peptides [25] [26] [27] from Helix-1 of ACE2, which are expected to maintain high α-helicity, have high binding affinity to SARS-CoV-2 RBD, and have improved antiviral activity and stability from proteolysis. We decided to use double stapling because of the relatively longer helical region that binds to the SARS-CoV-2 RBD. Double stapling has been reported to confer striking protease resistance 20, 28, 29 . Furthermore, Mourtada et al. recently

reported 2-4 fold enhancement of antimicrobial potency by double-stapled peptides over single stapling 23 . Double stapling was also reported to achieve improved pharmacokinetic profiles, including oral absorption of peptide-based HIV-1 fusion inhibitors 28 . For the i,i+4, and i,i+7

stapling, we used non-natural amino acids as illustrated in Figure 2 to introduce the hydrocarbon staples to Helix-1. The stapling sites were selected based on the binding site information of SARS-CoV-2 RBD with ACE2 (Helix-1) from the Cryo-EM and X-ray structure mentioned before so that they do not interfere with the critical binding site residues. We have synthesized (CPC Scientific, Inc.) four stapled peptides, as depicted in Figure 2 . We also synthesized the linear peptide, NYBSP-C, as a control. Besides, we purchased StRIP16 29 , which is a Rab8a GTPase-binding double-stapled peptide and unrelated to ACE2, to use as a control.

Due to the extended size of Helix-1, we decided to double staple Helix-1 of ACE2 to preserve the α-helical content of the peptides. To determine the helical propensity of these peptides, we resorted to CD spectroscopy for analyzing secondary structures. The Data in Figure   3 (A) indicate that all the stapled peptides had the maxima at 190 nm and two minima at 208 and 222 nm, confirming that all these stapled peptides had α-helical structure. The % helicity calculation shows remarkable improvement over the linear peptide. The data in Figure 3 

We used SPR to determine the binding affinity of one double-stapled peptide, NYBSP-4, with SARS-CoV-2 RBD. This method is useful in measuring the binding constant (K D ) as well as k on (also known as association constant, ka) and k off (also known as dissociation constant, k d ). We also used the linear peptide, NYBSP-C, as a control. Various concentrations of biotinylated SARS-CoV-2 RBD was manually printed onto the Chip (immobilization) via biotin-avidin conjugation.

Peptides were passed through the chip surface, and the signal changes (in AU) of each peptide at varied concentrations were recorded ( Figure 4A and B). The resulting data were fit to a 1:1 binding model, and the binding affinity K D and kinetic parameters k on and k off of the interaction of SARS-CoV-2 RBD with NYBSP-C and NYBSP-4 were determined ( Figure 4C ). The K D value of NYBSP-4 was 2.2 µM, which was very much in line with the antiviral activity we observed against SARS-CoV-2 pseudovirus (Table-1 ). As expected, the linear peptide, NYBSP-C, used as a control showed poor binding (73.7 µM), which was about 33.5-fold lower than NYBSP-4. The SPR analysis also confirmed that the double-stapled peptides bind directly to the SARS-CoV-2 RBD.

Proteolytic stability remains a potential concern in developing peptide-based therapy. We wanted to address this problem by introducing double stapling in Helix-1 of the ACE2 receptor.

Double stapling is known to enhance protection from proteolysis. However, it was prudent for us to test how the stapled peptides that we designed withstand the proteolysis in human plasma.

The peptides were incubated with human plasma at 37˚C, and the fragments formed from proteolysis were measured by LC-MS/MS at different time points (0,10, 30, 60, and 120 min). We used a small molecule drug, propantheline bromide, as an assay control. The data in Figure 5 shows that stapled peptide NYBSP-4 is highly stable during the time used for the assay. The calculated half-life (T 1/2 ) of NYBSP-4 was >289 min, but surprisingly, the linear control peptide NYBSP-C also showed similar stability (T 1/2 >289 min). Usually, small peptides are known to get proteolytically cleaved quickly. The unusual stability of the linear peptide in human plasma in our

test is yet to be understood.

We prepared SARS-CoV-2 pseudovirus capable of single-cycle infection by transfecting HEK293T/17 cells with an HIV-1 Env-deleted proviral backbone plasmid pNL4-3∆Env-NanoLuc and pSARS-CoV-2-S Δ19 plasmid 30 . The incorporation of the spike protein in the pseudovirus was validated by Western blot analysis using the SARS Spike Protein Antibody (Novus Biologicals) ( Figure 6A ). This antibody targets explicitly amino acids 1124-1140 of the spike protein S2. We found a specific band at 80 kDa, which identifies the subunit S2 and a second band at about 190 kDa, which corresponds to the full-length S protein (S1 + S2), as previously reported 31 had the lowest % α-helicity among all the stapled peptide designed, and it also showed the least antiviral activity. Moreover, none of the peptides showed activity against the control pseudovirus VSV-G ( Table 1 ), suggesting that their inhibitory activity is specific to SARS-CoV-2.

The cytotoxicity (CC 50 ) of the peptides was assessed in parallel with the inhibition assays. We found that the peptides did not induce any apparent cell toxicity at the highest dose tested. More specifically, <10% toxicity was detected at the higher dose used in this assay ( Table 1) .

Additionally, the antiviral activity of the peptides was evaluated by infecting Vero E6 cells with The suspension was kept at room temperature for 0.5 h, while a stream of nitrogen was bubbled through it. The mixture was filtered, and the resin was washed with DMF (6x20 mL). Fmoc-Asn(Trt)-OH (0.3 mmol) was pre-activated with DIC (0.3 mmol) and HOBt (0.3 mmol) in 10 mL DMF, then the mixture was added into the resin. The reaction was carried out in a nitrogen atmosphere. Kaiser ninhydrin test was used to indicate reaction completion. After the reaction was completed, the suspension was filtered, and the resin was washed with DMF (3x20 mL). After that, all sequences of amino acids were coupled and completed to give the peptidyl resin full protection, which was used to do the cyclization with Grubbs 1st catalyst. All crude peptides were purified by pre-HPLC to > 90% purity. They were acetylated at the C-terminus and amidated at the N-terminus. The molecular weight of all peptides was confirmed by electrospray mass spectrometry.

The secondary structure analysis to calculate % α-helicity was performed by Creative- 

The binding study of one double-stapled peptide, NYBSP-4, and the linear control peptide, The resulting data were fit to a 1:1 binding model using Biacore Evaluation Software (GE Healthcare).

The plasma stability study was performed by Creative-Biolabs (New York, NY, USA). In 

To confirm the incorporation of the spike protein into the SARS-CoV-2 pseudovirus, 2 mL of the pseudovirus-containing supernatant was ultra-centrifuged for 2 h at 38,000 rpm on a 20 % sucrose cushion to concentrate the viral particles. Viral pellets were lysed and processed for protein analysis. The viral proteins were resolved on a NuPAGE Novex 4-12 % Bis-Tris Gel Following 48 h incubation, 25 µL of the lysates were transferred to a white plate and mixed with 50 µL of a luciferase assay reagent. The luciferase activity was immediately measured.

The standard live virus-based microneutralization (MN) assay was used [38] [39] [40] values were calculated as above.

The current pandemic made it urgent to develop therapeutics urgently against COVID-19.

We took advantage of the structural knowledge of the binding site of SARS-CoV-2 RBD and the StRIP16, a ACE2-unrelated Rab8a GTPase-binding double-stapled peptide reported earlier 29 , was used as a control. 

Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19

Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension

Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects

CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

The first-inclass peptide binder to the SARS-CoV-2 spike protein

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Structural basis of receptor recognition by SARS-CoV-2

Stapled Peptides Inhibitors: A New Window for Target Drug Discovery

Stapled peptides as a new technology to investigate protein-protein interactions in human platelets

Stapled Peptides-A Useful Improvement for Peptide-Based Drugs

Design of antiviral stapled peptides containing a biphenyl cross-linker

Targeted covalent inhibitors of MDM2 using electrophile-bearing stapled peptides

Suppression of Breast Cancer Metastasis Using Stapled Peptides Targeting the WASF Regulatory Complex

Hydrocarbon stapled peptides as modulators of biological function

Cell Permeable Stapled Peptide Inhibitor of Wnt Signaling that Targets beta-Catenin Protein-Protein Interactions

Enhancing the Cell Permeability of Stapled Peptides with a Cyclic Cell-Penetrating Peptide

A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading

Stapled peptides for intracellular drug targets

Design of stapled antimicrobial peptides that are stable, nontoxic and kill antibiotic-resistant bacteria in mice

Affinity Stapled Peptides To Target the Repressor Activator Protein 1 (RAP1)/Telomeric Repeat-Binding Factor 2 (TRF2) Protein-Protein Interaction in the Shelterin Complex

Chemical synthesis of hydrocarbonstapled peptides for protein interaction research and therapeutic targeting

Activation of apoptosis in vivo by a hydrocarbonstapled BH3 helix

Hydrocarbon-stapled peptides: principles, practice, and progress

Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic

Protease-Resistant and Cell-Permeable Double-Stapled Peptides Targeting the Rab8a GTPase

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Quantitative analysis of protein far UV circular dichroism spectra by neural networks

Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system

Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes

Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity

l%20Archive/TCID50%20Determination%20-%20ARCHIVED_WM.pdf

High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models

A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein

Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. Sci Rep 2016, 6, 31629. of SARS-CoV-2 pseudovirus. Columns represent the means ± standard deviations (n =3). (C) Immunoblot analysis of cell lysates to evaluate ACE2 expression

Dose-Response plots of the antiviral activity of peptides in a single

Antiviral activity in (A) HT1080/ACE2 cells and (B) A549/ACE2 cells

Data on stapled peptides NYBSP-1, NYBSP-2, NYBSP-3, NYBSP-4, and a control Linear peptide NYBSP-C are shown as mean ± SD of three independent experiments

The study was conducted using an intramural fund to AKD from the New York Blood Center. We gratefully acknowledge the generous gift of cells (highly expressed ACE2) and several plasmids to create the pseudovirus from Dr. Paul Bieniasz of the Rockefeller University.

 Figure 2 . Design of Double-stapled peptides as anti-SARS-CoV-2 inhibitors. The linear peptide, NYBSP-C, and an ACE2-unrelated double-stapled peptide, StRIP16, 29 were used as controls.